Emory University

COVID-19 not only affects the CV health of infected patients, but it also affects the CV care of patients even in the absence of infection, according to two presentations at the virtual Heart in Diabetes Conference.

The most common type of pediatric central nervous system tumor, low-grade glioma, typically grows slowly and follows a relatively indolent course.

Inferior frontal lobe activation caused in addition to mental stress was independently linked to angina at baseline and during 2-year follow-up, researchers found.

Patients with valvular heart disease were satisfied with transcatheter aortic valve replacement and many made their treatment decisions with returning to active living in mind, according to a survey released by a patient advocacy group.

The FDA granted accelerated approval to belantamab mafodotin-blmf for treatment of relapsed or refractory multiple myeloma.

There are many ways in which women’s CV risk differs from that of men, and addressing it requires solutions tailored to women, according to a presentation at the virtual American Society for Preventive Cardiology Congress on CVD Prevention.

Induction therapy with lenalidomide, bortezomib and dexamethasone demonstrated high response rates after transplantation among 90% of a cohort of patients with myeloma, according to study results published in Journal of Clinical Oncology.

CVD prevention in Black adults, Hispanic adults and women are some of the many topics that will be discussed at this year’s virtual American Society for Preventive Cardiology Congress on CVD Prevention.

Venetoclax in combination with daratumumab and dexamethasone demonstrated a tolerable safety profile with encouraging efficacy among patients with multiple myeloma, according to research presented during ASCO2020 Virtual Scientific Program.

Patients with advanced non-small cell lung cancer who received nivolumab and ipilimumab demonstrated continued durable and long-term overall survival benefits compared with chemotherapy, according to data with 3-year minimum follow-up from the CheckMate 227 part 1 trial presented at the virtual ASCO Annual Meeting.